Email: cspc@cspc.cn
News
June 27, 2023
Share:
Previous: VOLUNTARY ANNOUNCEMENT - CHINA'S FIRST ANTI-GFRAL MONOCLONAL ANTIBODY JMT203 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Next: VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF OMALIZUMAB FOR INJECTION
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us